{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T08:37:42Z","timestamp":1789202262768,"version":"build-2803163510"},"reference-count":10,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/bmj.com\/coronavirus\/usage"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2021,8,24]]},"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:p>Remdesivir is an antiviral used for the treatment of COVID-19 requiring hospitalisation. Information on its cardiovascular safety profile is scarce. We report the case of a 37-year-old man with COVID-19 who developed bradycardia after receiving remdesivir. We recommend a baseline ECG for all patients prior to receiving remdesivir and continuous cardiac monitoring during treatment, especially among those with underlying cardiovascular disease, elderly and using \u03b2-blockers.<\/jats:p>","DOI":"10.1136\/bcr-2021-245289","type":"journal-article","created":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T12:17:56Z","timestamp":1630671476000},"page":"e245289","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":17,"title":["Remdesivir-associated bradycardia"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6106-2799","authenticated-orcid":false,"given":"Patrick R","family":"Ching","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Maryland Medical Center Midtown Campus, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calvin","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,9,3]]},"reference":[{"key":"2025082802431549000_14.9.e245289.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764"},{"key":"2025082802431549000_14.9.e245289.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110532"},{"key":"2025082802431549000_14.9.e245289.3","doi-asserted-by":"publisher","DOI":"10.1056\/NE-JMoa2007016"},{"key":"2025082802431549000_14.9.e245289.4","article-title":"Cardiac adverse events with remdesivir in COVID-19 infection","volume":"12","author":"Gupta","year":"2020","journal-title":"Cureus"},{"key":"2025082802431549000_14.9.e245289.5","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1016\/j.jaccas.2020.08.025","article-title":"Marked sinus bradycardia associated with remdesivir in COVID-19: a case and literature review","volume":"2","author":"Gubitosa","year":"2020","journal-title":"JACC Case Rep"},{"key":"2025082802431549000_14.9.e245289.6","first-page":"18","article-title":"Sinus bradycardia associated with remdesivir treatment in COVID-19: a case report and literature review","volume":"8","author":"Barkas","year":"2021","journal-title":"J Cardiovasc Dev Dis"},{"key":"2025082802431549000_14.9.e245289.7","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.210300"},{"key":"2025082802431549000_14.9.e245289.8","doi-asserted-by":"crossref","first-page":"791.e5","DOI":"10.1016\/j.cmi.2021.02.013","article-title":"Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns","volume":"27","author":"Touafchia","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"2025082802431549000_14.9.e245289.9","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA120.013679"},{"key":"2025082802431549000_14.9.e245289.10","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0b013e3181e0f8b2"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2021-245289","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T09:43:25Z","timestamp":1756374205000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2021-245289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":10,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9,3]]},"published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10.1136\/bcr-2021-245289"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2021-245289","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9]]}}}